| scholarly article | Q13442814 |
| P2093 | author name string | Konrad Reinshagen | |
| Patrick Hundsdoerfer | |||
| Georg Eschenburg | |||
| Birgit Appl | |||
| Doerte Langemann | |||
| Magdalena Trochimiuk | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer | Q24292870 | ||
| RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis | Q24299986 | ||
| IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis | Q24300707 | ||
| IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis | Q24300734 | ||
| cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms | Q24311676 | ||
| Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma | Q24602657 | ||
| c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation | Q24607621 | ||
| Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis | Q24609324 | ||
| Many stimuli pull the necrotic trigger, an overview | Q24613714 | ||
| Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition | Q28115131 | ||
| cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination | Q28284721 | ||
| The pathophysiology of mitochondrial cell death | Q29547893 | ||
| Identification of RIP1 kinase as a specific cellular target of necrostatins | Q29616006 | ||
| Apoptosis control by death and decoy receptors | Q33597389 | ||
| SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner | Q34229779 | ||
| Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody | Q35255233 | ||
| Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program | Q35659461 | ||
| The mitochondrial death pathway: a promising therapeutic target in diseases | Q35831981 | ||
| Advances in Risk Classification and Treatment Strategies for Neuroblastoma | Q36053801 | ||
| The inhibitors of apoptosis (IAPs) as cancer targets | Q36851057 | ||
| Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation | Q36954601 | ||
| Smac mimetics and TNFalpha: a dangerous liaison? | Q37005632 | ||
| IAP-targeted therapies for cancer | Q37302745 | ||
| Inhibitor of apoptosis proteins in hematological malignancies | Q37336610 | ||
| Targeting IAP proteins for therapeutic intervention in cancer | Q37980321 | ||
| Children's Oncology Group's 2013 blueprint for research: neuroblastoma | Q38068818 | ||
| Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells | Q38310891 | ||
| Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis | Q39366581 | ||
| Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. | Q39370420 | ||
| Requirement of nuclear factor κB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis | Q39412878 | ||
| NF-κB is required for Smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation-induced apoptosis | Q39486254 | ||
| The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs | Q39511129 | ||
| IKKbeta-mediated nuclear factor-kappaB activation attenuates smac mimetic-induced apoptosis in cancer cells | Q39840485 | ||
| Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. | Q41175043 | ||
| Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L. | Q41840140 | ||
| Recent advances in neuroblastoma | Q56637924 | ||
| XIAP, the guardian angel | Q74122492 | ||
| Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials | Q83381330 | ||
| Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors | Q87550003 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 50 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neuroblastoma | Q938205 |
| TNF | Q18032037 | ||
| P304 | page(s) | 87763-87772 | |
| P577 | publication date | 2017-09-23 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Sensitization of neuroblastoma for vincristine-induced apoptosis by Smac mimetic LCL161 is attended by G2 cell cycle arrest but is independent of NFκB, RIP1 and TNF-α. | |
| P478 | volume | 8 |
| Q58702896 | Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma |
| Q58749539 | FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells |
| Q58738705 | Mackerel-Derived Fermented Fish Oil Promotes Hair Growth by Anagen-Stimulating Pathways |
Search more.